Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutrition & Diabetes 2012;2(12):e54-e

Augustin M, Holland B, Dartsch D, et al. Adherence in the treatment of psoriasis: a systematic review. Dermatology 2011;222(4):363 – 74 Augustin M, Reich K, Yamauchi P, et al. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial. British Journal of Dermatology 2022; 186(6):942 – 954

Augustin M, Thaci D, Eyerich K, et al. Continued treatment with secukinumab is associated with high retention or regain of response. Br J Dermatol 2020;182(1):67 – 75

Augustin M, Reich K, Yamauchi P, et al. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial. British Journal of Dermatology 2022; 186(6):942 – 954

AWMF. S3 - Leitlinie zur Therapie der Psoriasis vulgaris 2021 Appendix A: „Topische Therapie, Phototherapie, Sonstige Therapien, Schnittstellendefinition“. 2015. https://www.awmf.org/uploads/tx_szleitlinien/013-001l_S3_Therapie-Psoriasis-vulgaris_2021-07-verlaengert_01.pdf, abgerufen am: 17.05.2022

AWMF. Therapie der Psoriasis vulgaris 2021. https://www.awmf.org/uploads/tx_szleitlinien/013-001l_S3_Therapie-Psoriasis-vulgaris_2021-07-ver- laengert_01.pdf, abgerufen am: 19.05.2022

Bagel J, Lebwohl M, Israel RJ, et al. Immunogenicity and skin clearance recapture in clinical studies of brodalumab. Journal of the American Academy of Dermatology 2020;82(2):344 – 51

Bartelds GM, Krieckaert CLM, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011;305(14):1460 – 8

Belinchon I, Rivera R, Blanch C, et al. Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature. Patient Prefer Adherence 2016;10:2357 – 67

Berkhout LC, Vogelzang EH, Hart MM, et al. The effect of certolizumab drug concentration and anti-drug antibodies on TNF neutralisation. Clin Exp Rheumatol 2020;38(2):306 – 13

Bewley A, Page B. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol 2011;25 Suppl 4:9 – 14

Bissonnette R, Luger T, Thaçi D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-se - vere psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol 2018;32(9):1507 – 14

Blauvelt A, Leonardi CL, Gooderham M, et al. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatology 2020;156(6):649 – 58

Blauvelt A, Reich K, Warren RB, et al. Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis. Br J Dermatol 2017;177(3):879 – 81

Brezinski EA, Armstrong AW. Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and inter - rupted biologic therapy. PLoS One 2012;7(4):e33486

Callis Duffin K, Mason MA, Gordon K, et al. Characterization of patients with psoriasis in challenging-to-treat body areas in the Corrona Psoriasis Registry. Dermatology 2021;237(1):46 – 55

Carroll CL, Feldman SR, Camacho FT, et al. Better medication adherence results in greater improvement in severity of psoriasis. Br J Dermatol 2004;151(4):895-7

Ceovic R, Mance M, Bukvic Mokos Z, et al. Psoriasis: female skin changes in various hormonal stages throughout life - puberty, pregnancy, and meno- pause. Biomed Res Int 2013;2013:571912

Chiu H-Y, Chu TW, Cheng Y-P, et al. The association between clinical response to ustekinumab and immunogenicity to ustekinumab and prior adalimumab. PloS one 2015;10(11):e0142930-e

Christophers E, Segaert S, Milligan G, et al. Clinical improvement and satisfaction with biologic therapy in patients with severe plaque psoriasis: results of a European cross-sectional observational study. J Dermatolog Treat 2013;24(3):193 – 8

Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 2020;395(10230):1115 – 25

Egeberg A, See K, Garrelts A, et al. Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort. BMC Dermatol 2020;20(1):3 EMA. Human medicine European public assessment report (EPAR) 2022. https://www.ema.europa.eu/en/medicines, abgerufen am: 30.05.2022

Emery P, Vencovský J, Sylwestrzak A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Annals of the Rheumatic Diseases 2017;76(1):51 – 7

Fachinfo-Service. 2022. https://www.fachinfo.de/, abgerufen am: 19.05.2022

Fagerli KM, Lie E, van der Heijde D, et al. Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study. Ann Rheum Dis 2013;72(11):1840 – 4

Feldman SR, Tian H, Wang X, et al. Health care utilization and cost associated with biologic treatment patterns among patients with moderate to severe psoriasis: analyses from a large U.S. claims database. J Manag Care Spec Pharm 2018; 10.18553/jmcp.2018.18308:1 – 11

Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19(3):210-6

Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978;157(4):238 – 44

Gambardella A, Licata G, Sohrt A. Dose adjustment of biologic treatments for moderate-to-severe plaque psoriasis in the real world: a systematic review. Dermatol Ther (Heidelb) 2021;11(4):1141 – 56

Garcês S, Demengeot J. The immunogenicity of biologic therapies. Curr Probl Dermatol 2018;53:37 – 48

Gehin JE, Goll GL, Warren DJ, et al. Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study. Arthritis Research & Therapy 2019;21(1):256

Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007;143(12):1493-9

Gisondi P, Del Giglio M, Cotena C, et al. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. Br J Dermatol 2008;158(6):1345 – 9

Gniadecki R, Teixeira HD, Geng Z. Adalimumab dose escalation, deescalation, and reescalation in patients in the REVEAL study. Journal of the American Academy of Dermatology 2016;74(5):AB234

Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. New England Journal of Medicine 2016;375(4):345 – 56

Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. The Lancet 2021;397(10273):475 – 86

Gordon KB, Gottlieb AB, Langely RG, et al. Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption. J Eur Acad Dermatol Venereol 2015;29(4):767 – 76

Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. The Lancet 2018;392(10148):650 – 61

Gottlieb AB, Blauvelt A, Thaçi D, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multi- center, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). J Am Acad Dermatol 2018;79(2):302-14.e6

Gustafson CJ, Watkins C, Hix E, et al. Combination therapy in psoriasis: an evidence-based review. Am J Clin Dermatol 2013;14(1):9 – 25

Herszényi K, Jókai H, Rencz F, et al. Antidrug antibody formation during tumor necrosis factor α inhibitor treatment of severe psoriatic patients in the real-life practice. Postepy dermatologii i alergologii 2019;36(5):589 – 94

Hsu L, Armstrong AW. Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response. Expert Rev Clin Immunol 2013;9(10):949 – 58

Hsu L, Snodgrass BT, Armstrong AW. Antidrug antibodies in psoriasis: a systematic review. Br J Dermatol 2014;170(2):261 – 73

Huang YW, Tsai TF. A drug safety evaluation of risankizumab for psoriasis. Expert Opin Drug Saf 2020;19(4):395 – 402

Jani M, Isaacs JD, Morgan AW, et al. High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-trea - ted patients with rheumatoid arthritis: results from the BRAGGSS cohort. Annals of the Rheumatic Diseases 2017;76(1):208 – 13

Jullien D, Prinz JC, Nestle FO. Immunogenicity of biotherapy used in psoriasis: the science behind the scenes. Journal of Investigative Dermatology 2015;135(1):31 – 8

Kamiya K, Kishimoto M, Sugai J, et al. Risk factors for the development of psoriasis. Int J Mol Sci 2019;20(18)

Kiedrowski R, Dirschka T, Kurzen H, et al. Empfehlungen für die ambulante Versorgung von Psoriasis vulgaris - Aktualisierter praxisnaher Behandlungs- pfad. Der Deutsche Dermatologe 2019;67:09 (Suppl.) 1 – 24

Kimball AB, Kerbusch T, van Aarle F, et al. Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab. Br J Dermatol 2020;182(1):180 – 9

Koo K, Nakamura M, Lebwohl M. Article commentary: the natural course of psoriasis: data from a rare ‘experiment of nature’ in Maoist China. Journal of Psoriasis and Psoriatic Arthritis 2017;2(3):39 – 40

Kuhn A, Ruland V, Patsinakidis N, et al. Use of methotrexate in patients with psoriasis. Clin Exp Rheumatol 2010;28(5 Suppl 61):S138 – 44

Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis - results of two phase 3 trials. N Engl J Med 2014;371(4):326 – 38

Langley RG, Poulin Y, Srivastava B, et al. Reduced risk of mortality associated with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): a nested case-control analysis. J Am Acad Dermatol 2021;84(1):60 – 9

Lebwohl M, Blauvelt A, Paul C, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). J Am Acad Dermatol 2018;79(2):266-76.e5

Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. New England Journal of Medicine 2015;373(14):1318 – 28

Lebwohl M, Thaçi D, Warren RB. Addressing challenges associated with long-term topical treatment and benefits of proactive management in patients with psoriasis. J Eur Acad Dermatol Venereol 2021;35 Suppl 1:35 – 41

Leonard DG, O'Duffy JD, Rogers RS. Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis. Mayo Clin Proc 1978;53(8):511 – 8

Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). The Lancet 2008;371(9625):1665 – 74

Lima H. Psoriasis: types, causes and medication. IntechOpen, 2013

Loeff FC, Tsakok T, Dijk L, et al. Clinical impact of antibodies against ustekinumab in psoriasis: an observational, cross-sectional, multicenter study. Journal of Investigative Dermatology 2020;140(11):2129 – 37

Mahé E. Optimal management of plaque psoriasis in adolescents: current perspectives. Psoriasis (Auckl) 2020;10:45 – 56

Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 2020;395(10230):1126 – 36

Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. Journal of the American Academy of Dermatology 2008;58(1):106 – 15

Miller DW, Feldman SR. Cost-effectiveness of moderate-to-severe psoriasis treatment. Expert Opin Pharmacother 2006;7(2):157 – 67

Moots RJ, Xavier RM, Mok CC, et al. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: results from a multinational, real-world clinical practice, non-interventional study. PloS one 2017;12(4):e0175207-e

Mrowietz U, Dieckmann T, Gerdes S, et al. ActiPso: definition of activity types for psoriatic disease: a novel marker for an advanced disease classification. J Eur Acad Dermatol Venereol 2021;35(10):2027 – 33

Nestle FO, Kaplan DH, Barker J. Psoriasis. New England Journal of Medicine 2009;361(5):496 – 509

Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). The Lancet 2008;371(9625):1675 – 84

Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to- severe plaque psoriasis. Br J Dermatol 2016;175(2):273 – 86

Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. British Journal of Dermatology 2005;152(6):1304 – 12

Puig L, Carrascosa JM, Belinchon I, et al. Adherence and patient satisfaction with topical treatment in psoriasis, and the use, and organoleptic properties of such treatments: a Delphi study with an expert panel and members of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr 2013;104(6):488 – 96

Puig L, Costanzo A, Muñoz-Elías EJ, et al. The biological basis of disease recurrence in psoriasis: a historical perspective and current models. Br J Der- matol 2022;186(5):773 – 81

Puzenat E, Bronsard V, Prey S, et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol 2010;24 Suppl 2:10 – 6

Quistrebert J, Hässler S, Bachelet D, et al. Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: a European retrospective multicohort analysis. Semin Arthritis Rheum 2019;48(6):967 – 75

Ragnarson Tennvall G, Hjortsberg C, Bjarnason A, et al. Treatment patterns, treatment satisfaction, severity of disease problems, and quality of life in patients with psoriasis in three Nordic countries. Acta Derm Venereol 2013;93(4):442 – 5

Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. The Lancet 2019;394(10201):831 – 9

Reich K, Korber A, Mrowietz U, et al. Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study. Br J Dermatol 2021a;184(5):849 – 56

Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366(9494):1367 – 74

Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. The Lancet 2017;390(10091):276 – 88

Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis. New England Journal of Medicine 2021b;385(2):142-52

Ribera M, Dauden E, Puig L, et al. [Design and validation of a questionnaire to measure treatment satisfaction in patients with moderate-to-severe psoriasis: the NEODERMA study]. Actas Dermosifiliogr 2011;102(1):28 – 38

Sarma N. Evidence and suggested therapeutic approach in psoriasis of difficult-to-treat areas: palmoplantar psoriasis, nail psoriasis, scalp psoriasis, and intertriginous psoriasis. Indian J Dermatol 2017;62(2):113 – 22

Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008;158(3):558 – 66

Schaarschmidt ML, Kromer C, Herr R, et al. Treatment satisfaction of patients with psoriasis. Acta Derm Venereol 2015;95(5):572 – 8

Schmitt-Egenolf M, Freilich J, Stelmaszuk-Zadykowicz NM, et al. Drug persistence of biologic treatments in psoriasis: a Swedish national population study. Dermatol Ther (Heidelb) 2021;11(6):2107 – 21

Shahwan KT, Kimball AB. Managing the dose escalation of biologics in an era of cost containment: the need for a rational strategy. Int J Womens Dermatol 2016;2(4):151 – 3

Stewart TJ, Tong W, Whitfeld MJ. The associations between psychological stress and psoriasis: a systematic review. Int J Dermatol 2018;57(11):1275-82

Thaçi D, Ortonne J-P, Chimenti S, et al. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimu - mab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. British Journal of Dermatology 2010;163(2):402 – 11

Thomas LW, Lee EB, Wu JJ. Systematic review of anti-drug antibodies of IL-17 inhibitors for psoriasis. J Dermatolog Treat 2019;30(2):110 – 6

Tiwari V, Brent LH. Psoriatic arthritis. (Hrsg.), StatPearls. Treasure Island (FL), 2022

Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. The Lancet 2006;367(9504):29 – 35

Valenzuela F, Flores R. Immunogenicity to biological drugs in psoriasis and psoriatic arthritis. Clinics (Sao Paulo, Brazil) 2021;76:e3015-e van Cranenburgh OD, de Korte J, Sprangers MA, et al. Satisfaction with treatment among patients with psoriasis: a web-based survey study. Br J Dermatol 2013;169(2):398 – 405

van den Reek JM, van Luumig PP, Otero ME, et al. Satisfaction of treatment with biologics is high in psoriasis: results from the Bio-CAPTURE network. Br J Dermatol 2014;170(5):1158 – 65

Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus adalimumab in plaque psoriasis. New England Journal of Medicine 2021;385(2):130-41

Zachariae C, Mørk NJ, Reunala T, et al. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol 2008;88(5):495 – 501

Zhu Y, Marini JC, Song M, et al. Immunogenicity of guselkumab is not clinically relevant in patients with moderate-to-severe plaque psoriasis. J Invest Dermatol 2019;139(8):1830 – 4.e6

Zschocke I, Mrowietz U, Karakasili E, et al. Non-adherence and measures to improve adherence in the topical treatment of psoriasis. J Eur Acad Dermatol Venereol 2014;28 Suppl 2:4 – 9